News

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation long-acting injectables (LAI) across multiple therapeutic areas and indications.

Medincell is expected to use its commercial-stage LAI technology platform to formulate the potential innovative therapies, meaning it will be responsible for formulation activities and preclinical studies. Meanwhile, AbbVie will finance and conduct the clinical development for the programmes and will be responsible for regulatory approval, manufacturing and commercialisation.

Christophe Douat, chief executive officer of Medincell, commented: “This will be an exciting partnership with one of the most innovative and successful pharmaceutical companies. Medincell has entered a new period of growth following the US Food and Drug Administration (FDA) approval of the first product using our technology in April 2023. The full potential of long-acting injectable therapies is getting increasingly recognised.”

Sébastien Enault, Medincell’s chief business officer, added: “Our business development is accelerating following FDA approval of our first product. Our technology can help harvest the full potential of many known or yet untapped drugs. We are ready to make this exciting partnership very successful.”

Under the terms of this new agreement, Medincell will receive an upfront payment of $35m and is eligible for up to $1.9bn in development and commercial milestone payments. It is also eligible for mid-single to low-double-digit royalties on net sales.